ArisGlobal Announces Continued Growth with New Global Offices
Organization Opens New Offices in Belgium and Ireland
STAMFORD, CT—JUNE 25, 2012—ArisGlobal, a provider of solutions to the life science industry, announced the opening of two new offices in Antwerp, Belgium and Dublin, Ireland.
These new offices will allow the company to continue its growth and expansion in several product areas including pharmacovigilance and risk management, clinical data management and operations, regulatory affairs, and medical information management.
“We continue to grow with the addition of new customers and the development of new products and offerings. This expansion has created the need for an even broader global presence and new space in several regions of the world,” commented Vice President of European Operations, Simon Sparkes. “This expansion will help us to deliver added value to our customers and further execute on our vision of a suite of integrated life science software and services meeting the diverse needs of organizations around the world.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
